Takeda's bone cancer medicine Mepact gains NICE recommendation.
M2 PHARMA-September 8, 2011-Takeda's bone cancer medicine Mepact gains NICE recommendation(C)2011 M2 COMMUNICATIONS
8 September 2011 - The National Institute for Health and Clinical Excellence (NICE) said yesterday it has published final draft guidance recommending the use of Japanese Takeda Pharmaceutical Company Limited's (TYO:4502) Mepact (mifamurtide).
More specifically, the UK agency is recommending the use of Mepact in combination with postoperative multi-agent chemotherapy as an option for treating high-grade resectable non-metastatic osteosarcoma (bone cancer), when it's made available at a reduced cost to the NHS under a patient access scheme.
NICE has not yet issued final guidance to the NHS, it added.
Following a clarification from the NICE Board on how discounting is applied (which involves assessing the way in which health benefits are valued and calculated over a very long period of time) the independent Appraisal Committee has re-examined the evidence for this appraisal.
The evidence indicated that mifamurtide, when added to the usual treatment with surgery and chemotherapy, increases the number of patients who are effectively cured of their cancer. Although the number of additional patients who would benefit in this way is small and uncertain, the treatment effects are both substantial in restoring health and sustained over a very long period - the patients who are cured continue to benefit for the rest of their lives, NICE added.
The clarification from the Board provided guidance on how discount rates can be applied in this circumstance.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 8, 2011|
|Previous Article:||Abbott begins study of ABSORB bioresorbable vascular scaffold in BTK critical limb ischemia.|
|Next Article:||Gilead terminates dosing GS 9190 with pegylated interferon, ribavirin for hepatitis C clinical trials.|